Tango Therapeutics, Inc. (TNGX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Tango Therapeutics is a precision oncology company focused on developing novel drugs targeting tumor suppressor gene loss. The company has no approved products and has not generated revenue from product sales. Its primary revenue source is a collaboration agreement with Gilead Sciences, Inc.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $3.2 million | $19.9 million | $8.6 million | $26.3 million |
| Net Loss | $(38.9) million | $(25.6) million | $(78.7) million | $(63.5) million |
| Net Loss Per Share | $(0.35) | $(0.24) | $(0.71) | $(0.58) |
| Operating Expenses | $44.1 million | $49.4 million | $92.1 million | $98.2 million |
| Cash & Marketable Securities | $180.8 million (as of June 30, 2025) | |||
| Accumulated Deficit | $(580.3) million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased significantly year-over-year. Q2 2025 revenue was $3.2 million compared to $19.9 million in Q2 2024. The prior year included a one-time $12.1 million license fee from Gilead, which did not recur in the current period.
- Expense Reduction: Operating expenses decreased by $5.3 million in Q2 2025 compared to Q2 2024. This was primarily driven by the discontinuation of the TNG908 and TNG348 clinical programs and lower discovery costs, partially offset by increased spending on the TNG462 program.
- Increased Net Loss: Despite lower expenses, the net loss widened to $38.9 million in Q2 2025 from $25.6 million in Q2 2024, largely due to the absence of the license revenue recognized in the prior year.
- Cash Position: Cash and cash equivalents decreased from $69.5 million at year-end 2024 to $39.3 million at June 30, 2025, while marketable securities decreased from $188.4 million to $141.5 million.
Guidance, Outlook, and Risks
- Liquidity Runway: Management expects existing cash, cash equivalents, and marketable securities ($180.8 million) to fund operations into the first quarter of 2027.
- Subsequent Event (Gilead Amendment): On August 4, 2025, the company and Gilead mutually agreed to truncate the research term of their collaboration from seven to five years. This change has no financial penalty, and the remaining unrecognized deferred revenue of $53.8 million will be recognized as revenue in Q3 2025.
- Clinical Pipeline Updates:
- TNG462: Ongoing Phase 1/2 monotherapy trial; combination trials with Revolution Medicines' RAS(ON) inhibitors initiated in June 2025. Data update expected in H2 2025.
- TNG456: First patient treated in May 2025 for CNS cancers (GBM focus).
- TNG260: Enrolling in dose expansion for STK11-mut lung cancer; data expected in H2 2025.
- Risks:
- Regulatory & Government Funding: Risks associated with potential FDA/SEC funding shortages or government shutdowns delaying reviews.
- Supply Chain: Reliance on WuXi AppTec as the sole source of API for clinical-stage candidates, subject to potential U.S. legislative restrictions.
- Capital Needs: Continued need for substantial additional funding to advance programs and commercialize products.
Key Facts for Investor Verification
- Verify the timing and magnitude of the $53.8 million revenue recognition expected in Q3 2025 following the Gilead agreement amendment.
- Monitor the cash burn rate relative to the stated runway into Q1 2027, given the significant operating losses.
- Track progress of the TNG462 combination trials and the upcoming H2 2025 data readouts for TNG462 and TNG260.
- Assess the impact of potential legislative actions regarding WuXi AppTec on the company's ability to manufacture clinical supplies.
- Review the status of the One Big Beautiful Bill (OBBB) tax legislation signed in July 2025 and its impact on R&D expense capitalization.